Introduction 25
The neurotrophin, brain-derived neurotrophic factor (BDNF) is an attractive therapeutic for many 26 neurodegenerative diseases due to its broad neuroprotective effects promoting neuronal survival, 27 synaptic plasticity and central nervous system (CNS) myelination (Chao, 2003; Fletcher et al., 2018b ; 28 Longo and Massa, 2013 for remyelinating therapies to halt disease progression. However, BDNF itself has poor 32 pharmacokinetic properties; it is non-selective, also acting through the pan-neurotrophic receptor 33 p75 NTR , has a short-half life and has high molecular weight, limiting its ability to penetrate the blood-34 brain barrier (Longo and Massa, 2013; Poduslo and Curran, 1996) . To overcome these limitations a 35 range of small molecule BDNF-mimetics that selectively target the TrkB receptor have been 36
developed (Longo and Massa, 2013) . This includes tricyclic dimeric peptide-6 (TDP6) Here, we compare the effect of intra-cerebroventricular (ICV) administration of these BDNF 50 mimetics following cuprizone demyelination in mice. Both mimetics promoted remyelination, in 51 particular myelin sheath thickness, after one-week recovery. Interestingly, LM22A-4 increased the 52 density of oligodendroglia in the corpus callosum more than TDP6. Importantly, these effects were 53 dependent on TrkB, as post-cuprizone treatment with LM22A-4 in mice with conditional deletion of 54
TrkB from oligodendrocytes abrogated the effects on both remyelination and oligodendroglial 55 density. While this indicates that LM22A-4 promotes myelin repair in a TrkB dependent manner, 56 assessment of TrkB phosphorylation and signaling in vitro suggests that LM22A-4 may not activate 57
TrkB directly, but rather result in delayed TrkB transactivation via a GPCR-mediated mechanism. 58
Collectively these data further verify that targeting TrkB activation is a cogent strategy to promote 59 myelin repair in the brain, and that alternate small molecule mimetic strategies are effective towards 60 this end. Further studies aimed at elucidating the precise mechanism of action are warranted to 61 optimize the therapeutic potential of this approach. 62 2
Materials and Methods 64

Experimental animals and cuprizone induced demyelination 65
Female C57BL/6 mice aged 8 weeks were fed 0.2% cuprizone in normal chow (Teklad Custom  66 Research Diets, USA) for 6 weeks to induce demyelination. Following stereotaxic surgery all mice were placed in a recovery chamber maintained at 32°C and 84
were monitored for adverse reactions immediately following surgery and then daily. After 7 days of 85 ICV infusion, mice were taken for necropsy and brain removed for immunostaining and electron 86 microscopy (EM). 87
Tissue processing and immunofluorescence 88
Mice were anaesthetized and transcardially perfused with 0.1M sterile mouse isotonic phosphate 89 buffered saline (PBS) followed by 4% paraformaldehyde (PFA). Brains were collected and post-90 fixed overnight in 4% PFA. The first millimeter of the right hemisphere from the sagittal midline was 91 selected for EM processing as previously described (Fletcher et al., 2018a) . The remaining tissue and 92 contralateral hemisphere were cryoprotected in 30% sucrose prior to embedding in OCT. Frozen 93 sections were cut in the sagittal orientation at 10µm thickness using a cryostat maintained between -94 20 to -17°C and collected on SuperfrostPlus slides, air-dried and stored at -80°C until use. 95
Approximately 70-100µm separated adjacent sections on each slide. 96
Immunofluorescent staining was performed as previously described (Fletcher et al., 2018a) . Briefly, 97 slides were washed in PBS before overnight incubation at room temperature with primary antibodies. 98
Slides were then washed and incubated with the appropriate fluorophore-conjugated secondary 99 antibody for 2 hours at room temperature in the dark. Slides were washed, and counterstained with 100 nuclear marker Hoescht33442 before mounting with aqueous mounting media (DAKO 
SDS-PAGE and Western blot analysis 165
Lysates were separated by SDS-PAGE (4-12% Bis-Tris, Invitrogen) and transferred to PVDF 166 membrane and probed with antibodies against TrkB (1:1000, sc-8316, SantaCruz) and pTrkB s478 167
(1:1000, R-1718-50, Biosensis), p44/42 MAPK (ERK1/2, 1:1000, #9102 Cell Signaling 168 Technologies) and phosphorylated ERK1/2 (pERK1/2, 1:1000, #9101 Cell Signaling Technologies). 169
All blots shown are representative of at least 3 independent experiments. Optical density value for 170 each band was determined using FIJI/ImageJ and corrected to loading control and normalized against 171 the relevant control condition. 172
Statistical analyses 173
Data were analyzed by unpaired t-test, 1-way ANOVA or mixed effect models for repeated measures 174 (GraphPad Prism 8), to test the effect of TrkB agonist treatments with post-hoc multiple comparisons 175 as appropriate. Statistical significance was set as p<0.05. 176 3 Results 177
LM22A-4 and TDP6 increase myelin sheath thickness during remyelination 178
We have previously shown treatment with TDP6, a structural mimetic of BDNF, enhances the 179 number of axons remyelinated and increases myelin sheath thickness during recovery after 6-weeks 180 cuprizone challenge in an oligodendroglial-TrkB dependent manner (Fletcher et al., 2018a) . Here, we 181 compared TDP6 with LM22A-4, a small molecule TrkB agonist reported to be a functional BDNF-182 mimetic (Massa et al., 2010) . Demyelination by cuprizone feeding was confirmed by myelin basic 183 protein (MBP) immunostaining, with severely reduced levels of MBP expression observed in animals 184 taken at 6 weeks of cuprizone feeding (minimum = 2/cohort; Figure S2 ). Cuprizone feed was 185 withdrawn and remaining animals received ICV minipumps containing aCSF (artificial cerebrospinal 186 fliud), TDP6 (40µM) or LM22A-4 (500µM) for 7 days. 187
To examine the extent of remyelination, MBP-immunostaining in the caudal corpus callosum was 188 assessed. This revealed both TDP6 and LM22A-4 treatment increased (p<0. post-mitotic oligodendrocytes, respectively (Fig. 3A) . This revealed that TDP6 and LM22A-4 230 infusions were successful, with an increased proportion of pTrkB S478+ cells in the corpus callosum 231 during remyelination, compared to the aCSF vehicle (Fig. 3B, p=0 .0022). Assessment of the 232 proportion of pTrkB S478+ cells positive for the OPC marker PDGFRα indicated treatment with TDP6 233 and LM22A-4 had no effect on TrkB activation on OPCs (Fig. 3C, p=0.21) Immunostaining for MBP revealed that LM22A-4 treatment in the oligodendroglial TrkB knockout 247 mice had no effect on the percentage area of MBP + immunostaining compared to the aCSF vehicle 248 (Fig. 4A , quantified in Fig. 4B, p=0.21) . Similarly, EM analysis (Fig. 4D) revealed there was no 249 change in the proportion of axons myelinated with LM22A-4 treatment (Fig. 4C, p=0.85) ) or the 250 mean g-ratio (aCSF: 0.77 ± 0.087; LM22A-4: 0.78 ± 0.088, p=0.90, n=3-4/group, unpaired t-test). 251
These data are consistent with oligodendroglial TrkB expression being necessary for LM22A-4 to 252 increase myelin sheath thickness during remyelination. 253
To determine if LM22A-4 treatment increased oligodendroglial populations during remyelination in 254 oligodendroglial TrkB knockout mice, triple immunolabelling for Olig2-PDGFRα-CC1 was 255 performed in the contralateral caudal corpus callosum (Fig. 5A) . Counts revealed that LM22A-4 256 treatment had exerted no change in the density of Olig2 + oligodendroglia (p=0.91; Fig. 5B To examine TrkB phosphorylation in LM22A-4 treated oligodendroglial TrkB knockout mice, 264 immunohistochemistry for pTrkB S478 with oligodendrocyte markers PDGFRα and CC1 was 265 performed (Fig. 6A) . Analysis of the caudal corpus callosum revealed that in the oligodendroglial 266
TrkB knockout mice LM22A-4 treatment did not increase the proportion of pTrkB S478+ cells 267 compared to the aCSF vehicle (Fig. 6B, p=0.24 ). This was also reflected with no change in the 268 proportion of pTrkB S478+ cells positive for oligodendroglial markers PDGFRα (p=0.99; Fig. 6C ) or 269 CC1 (p>0.99; Fig. 6D ). These data indicate that for LM22A-4 mediated TrkB phosphorylation during 270 remyelination requires oligodendroglial TrkB expression. 271
TrkB signaling dynamics initiated by LM22A-4 do not mimic BDNF 272
To determine if LM22A-4 elicits a signaling cascade mimicking typical BDNF-TrkB signaling, we 273 generated an isogenic stable TrkB expressing HEK293 (293-TrkB) cell line using the Flp-In system 274 ( Supplementary Fig. 1A ). Fig. 1B ). To confirm that the 293-TrkB cells responded to 279 BDNF, cells were treated with BDNF (0.04nM to 40nM) for 15 mins ( Supplementary Fig. 1C ) which 280 resulted in increasing levels of TrkB and ERK1/2 phosphorylation ( Supplementary Fig. 1D ). 281
As determined in the original report characterizing LM22A-4 as functional BDNF mimetic (Massa et  282 al., 2010), we used 500nM as the standard concentration for our in vitro studies. The 293-TrkB cells 283
were treated with 4nM BDNF or 500nM LM22A-4 for a time course of 5, 15, 30, 60 and 240mins 284
and assessed for TrkB and ERK1/2 phosphorylation by Western blot (Fig. 7A) . Densitometric 285 analysis (Fig. 7B) revealed that compared to BDNF treatment, which increased TrkB 286 phosphorylation within 5mins (p=0.012), LM22A-4 did not significantly increase levels of 287 phosphorylated TrkB until 240mins of treatment (p=0.02). The effects of LM22A-4 treatment on 288 ERK1/2 phosphorylation where levels peaked at 5mins of treatment, and significantly declined 289 compared to BDNF from 15 to 240mins (Fig. 7C) , 2011) . This 325 appears to contrast our observations, where exogenous BDNF or TDP6 exerted no effect on the 326 density or proliferative fraction of OPCs during remyelination after cuprizone (Fletcher et al., 2018a ). 327
The different observations between these two distinct experimental approaches may ultimately reflect 328 context, wherein oligoendroglia subjected to a lifetime of BDNF haploinsufficiency simply behave 329 differently. 330
The selective influence that LM22A-4 exerted upon OPCs remains to be explained. The doses used 331 for TDP6 and LM22A-4 were determined from reported concentrations required for these 332 compounds to mimic the neurotrophic activity of BDNF in in vitro myelinating co-culture or 
instances, but it is critical to distinguish growth in myelin thickness as an oligodendrocyte-driven 355 function (Ishii et al., 2012) . To date, a direct axonal signal that instructs oligodendrocytes to increase 356 myelin thickness has not been identified, although the number of myelin wraps is known to increase 357 as circuit activity increases with the maturing brain (Sturrock, 1980) . The extended 4-hour timeframe required to detect TrkB phosphorylation following LM22A-4 381 treatment in vitro is consistent with Trk-receptor transactivation, where it can take up to 6 hours to 382 elicit detectable Trk receptor phosphorylation, and results in signal bias towards Akt (Lee and Chao, 383 2001) . We propose that LM22A-4 is mediates its increase in OPC density during remyelination by 384
Trk-transactivation potentially via GPCRs (Fig. 8) 
